Parkinson’s Drug Treatments Will Reach $3471m In 2020 New Study Predicts

06 September 2018
Pharma

A new report by visiongain forecasts worldwide sales of drugs to treat Parkinson’s disease will reach $3471 million in 2020. That revenue prediction and others appear in Parkinson’s Disease: World Drug Industry and Market 2016-2026, published in May 2016. Visiongain is a business information company based in London, UK.

Visiongain forecasts the overall market for Parkinson’s disease (PD) therapies will grow steadily to 2026. Rising disease prevalence, due to ageing populations will stimulate the market. Advances in technology and development of new drug targeting will further augment the drug market for the treatment of Parkinson’s disease. The research and development (R&D) pipeline holds promise too, especially for disease-modifying agents.

Current treatment options offer symptomatic relief, with dopamine-regulating drugs dominating the market. Visiongain forecasts the emphasis on dopamine will gradually shift to the emergence of two new drug classes, which show potential of addressing neuroprotective and disease modifying paradigms. At the moment Deep Brain Stimulation (DBS), a medical device, offers effective symptom relief and long term treatment. DBS has been shown to help alleviate some of the most common and debilitating symptoms of Parkinson’s disease such as tremor, rigidity, stiffness, slowed movement, walking problems and some of the negative symptoms of other PD therapeutics, such as levodopa. In the next decade, stem cell therapies, such as those which are being developed by the International Stem Cell Corporation (ISCO) offer disease modifying potential. This has major implications on the industry as it may provide the cure millions of Parkinson’s disease patients around the world are hoping for.

Arvind Deol, a pharmaceutical & medical device analyst in visiongain, said:

“The Parkinson’s disease market holds much potential. An increase in prevalence and an unprecedented elder population provides the market room to grow and a consistent consumer base. The advent of generic alternatives has brought with it the final years of the current generation of blockbuster Parkinson’s disease medications, as a reduction in healthcare spending in key markets continues to drive generic growth.

Ultimately, the current generation of Parkinson’s disease pharmaceuticals, designed to help relieve symptoms, is coming to an end. Within the next decade, the advent of disease modifying therapies will reshape the Parkinson’s disease industry. Overall the Parkinson’s disease market is expected to grow with a CAGR of 1% from 2015-2026.”

Visiongain’s new report finds the Parkinson’s treatment market will change by 2026, with new mechanisms of drug action capturing sales. Also biomarkers will help validate trials of neuroprotective agents and prove disease modification.

That study shows revenue forecasts to 2026 at overall world market, submarket, product and national level. It forecasts world sales for the following segments:

• Dopaminergic agents
• Dopamine receptor agonists
• COMT inhibitors
• MAO inhibitors
• Treatments with other modes of action (grouped).

That investigation also analyses leading companies there, including GSK, Novartis, Orion Pharmaceuticals, Boehringer Ingelheim and Teva Pharmaceutical Industries.

The analysis discusses R&D and commercial progress, shows research interviews and predicts PD drug revenues to 2026 in leading national markets. That work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC nations).

Parkinson’s Disease: World Drug Industry and Market 2016-2026 adds to visiongain’s portfolio of reports on healthcare industries. Together those studies assess commercial potentials of pharmaceuticals, diagnostics and medical devices.

Recent News

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever